<DOC>
	<DOCNO>NCT00065728</DOCNO>
	<brief_summary>The purpose study investigate long-term efficacy safety posterior juxtascleral injection open label Anecortave Acetate 15mg administer every 6 month .</brief_summary>
	<brief_title>Open-Label Posterior Juxtascleral Injections Anecortave Acetate 15mg Dose Long Term Use Patients With AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>Patients subfoveal exudative agerelated macular degeneration ( AMD ) previously enrol longterm study anecortave acetate . Other protocoldefined inclusion criterion may apply . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>Anecortave</keyword>
	<keyword>Acetate</keyword>
	<keyword>Wet form age-related macular degeneration</keyword>
	<keyword>CNV</keyword>
	<keyword>Anecortave Acetate</keyword>
</DOC>